Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11857534 Inhibition of dipeptide repeat proteins

Patent 11857534 was granted and assigned to ALS Therapy Development Institute on January, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

ALS Therapy Development Institute

0

Current Assignee

ALS Therapy Development Institute

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Alan Premasiri0

Fernando G. Vieira0

Anna Gill0

Date of Patent

January 2, 2024

0

Patent Application Number

175845220

Date Filed

January 26, 2022

0

Patent Citations

US Patent 9023883 PRMT1 inhibitors and uses thereof

0

US Patent 9029343 Modulators of histone methyltransferase, and methods of use thereof

0

US Patent 9045455 Arginine methyltransferase inhibitors and uses thereof

0

US Patent 9120757 Arginine methyltransferase inhibitors and uses thereof

0

US Patent 9133189 Arginine methyltransferase inhibitors and uses thereof

0

US Patent 9221794 PRMT5 inhibitors and uses thereof

0

US Patent 9346761 Arginine methyltransferase inhibitors and uses thereof

0

US Patent 9346802 CARM1 inhibitors and uses thereof

0

...

Patent Primary Examiner

0

CPC Code

0

0

Patent abstract

Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs).

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11857534 Inhibition of dipeptide repeat proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.